Epizyme, Inc. (45)

Browse by Contract Category

Contracts

Form of Option Agreement under the 2022 Equity Incentive Plan (Filed With SEC on August 9, 2022)
Amendment No. 1 to License Agreement between the Company and HUTCHMED Group Investment Limited (formerly known as Hutchison China MediTech Investment Limited) (Filed With SEC on August 9, 2022)
Form of Contingent Value Rights Agreement (Filed With SEC on June 27, 2022)
Agreement and Plan of Merger, dated as of June 27, 2022, by and among the Parent, the Purchaser and the Company (Filed With SEC on June 27, 2022)
Epizyme, Inc. 2013 Employee Stock Purchase Plan, as amended and effective September 1, 2022 (Filed With SEC on May 19, 2022)
Fifth Amendment to Lease dated as of August 11, 2021, by and between the Company and ARE-TECH Square, LLC (Filed With SEC on August 16, 2021)
Amended and Restated Collaboration and License Agreement dated as of March 12, 2015, by and between the Registrant and Eisai Co. Ltd (Filed With SEC on February 23, 2021)
Consulting Agreement by and among Epizyme, Inc., BioStrategy, LLC, and Shefali Agarwal dated April 6, 2022 (Filed With SEC on August 9, 2022)
Form of Support Agreement (Filed With SEC on June 27, 2022)
Epizyme, Inc. 2022 Equity Incentive Plan (Filed With SEC on May 19, 2022)
Executive Severance and Change in Control Plan, as amended (Filed With SEC on May 10, 2022)
Employment Offer Letter dated March 11, 2022 between the Registrant and Jerald Korn (Filed With SEC on May 10, 2022)
First Amendment to the Companion Diagnostics Agreement dated October 23, 2013 between the Registrant and Eisai Co. Ltd. on the one side and Roche Molecular Systems, Inc. on the... (Filed With SEC on March 1, 2022)
Companion Diagnostics Agreement dated as of December 18, 2012 between the Registrant and Eisai Co., Ltd. on the one side and Roche Molecular Systems, Inc. on the other side (Filed With SEC on March 1, 2022)
Consulting Agreement, dated October 27, 2021, by and between the Registrant and Matthew Ros (Filed With SEC on March 1, 2022)
Second Amendment to the Companion Diagnostics Agreement dated November 16, 2015 between the Registrant and Eisai Co. Ltd. on the one side and Roche Molecular Systems, Inc. on the... (Filed With SEC on March 1, 2022)
Consulting Agreement, dated October 1, 2021, by and between the Registrant and Victoria Vakiener (Filed With SEC on March 1, 2022)
Underwriting Agreement, dated January 26, 2022, by and among the Company and Jefferies, LLC, as representative of the several Underwriters (Filed With SEC on January 27, 2022)
License Agreement dated August 7, 2021 between the Registrant and Hutchison China MediTech Investment Limited (Filed With SEC on November 9, 2021)
Employment Offer Letter dated August 4, 2021 between the Company and Grant Bogle (Filed With SEC on November 9, 2021)
Consulting Agreement dated August 4, 2021 between the Company and Robert B. Bazemore (Filed With SEC on November 9, 2021)
Form of Restricted Stock Unit Agreement (Inducement Grant) (Filed With SEC on November 9, 2021)
Form of Stock Option Agreement (Inducement Grant) (Filed With SEC on November 9, 2021)
Form of Restricted Stock Unit Agreement under 2013 Stock Incentive Plan (Filed With SEC on May 6, 2021)
Form of Stock Option Agreement under 2013 Stock Incentive Plan (Filed With SEC on May 6, 2021)
Amended and Restated Loan Agreement dated as of November 3, 2020 by and among the Registrant and BioPharma Credit Investments V (Master) LP, BPCR Limited Partnership and BioPharma... (Filed With SEC on February 23, 2021)
Non-Employee Director Compensation Program, effective January 1, 2021 (Filed With SEC on February 23, 2021)
Employment Offer Letter between the Company and Victoria Vakiener, dated October 23, 2018 (Filed With SEC on February 23, 2021)
Amendment No. 2 to Collaboration Agreement dated September 17, 2020 by and between the Company and Boehringer Ingelheim International GmbH (Filed With SEC on November 6, 2020)
Employment Offer Letter between the Company and Jeffery Kutok, dated February 21, 2020 (Filed With SEC on May 4, 2020)
Amendment to Collaboration Agreement dated March 10, 2020 by and between the Company and Boehringer Ingelheim International GmbH (Filed With SEC on May 4, 2020)
First Amendment to 2013 Stock Incentive Plan (Filed With SEC on May 4, 2020)
Description of Securities of the Registrant (Filed With SEC on February 27, 2020)
Guaranty and Security Agreement dated as of November 18, 2019 by and between the Registrant and BioPharma Credit PLC (Filed With SEC on February 27, 2020)
Warrant Agreement dated as of November 4, 2019 by and between the Registrant and RPI Finance Trust (Filed With SEC on February 27, 2020)
Purchase Agreement dated as of November 4, 2019 by and between the Registrant and RPI Finance Trust (Filed With SEC on February 27, 2020)
Loan Agreement dated as of November 4, 2019 by and between the Registrant and BioPharma Credit Investments V (Master) LP and BioPharma Credit PLC (Filed With SEC on February 27, 2020)
Non-Employee Director Compensation Program (Filed With SEC on August 9, 2019)
Employment Offer Letter between the Company and Paolo Tombesi, dated July 1, 2019 (Filed With SEC on August 9, 2019)
Underwriting Agreement related to the Common Offering, dated March 6, 2019, by and among the Company and Jefferies, LLC, Citigroup Global Markets, Inc. and Cowen and Company, as... (Filed With SEC on March 7, 2019)
Form of Series A Preferred Stock Certificate (Filed With SEC on March 7, 2019)
Underwriting Agreement related to the Preferred Offering, dated March 6, 2019, by and among the Company and Jefferies, LLC, Citigroup Global Markets, Inc. and Cowen and Company,... (Filed With SEC on March 7, 2019)
Executive Severance and Change in Control Plan (Filed With SEC on February 26, 2019)
Non-Employee Director Compensation Program (Filed With SEC on February 26, 2019)
Form of Restricted Stock Unit Agreement under 2013 Stock Incentive Plan (Filed With SEC on February 26, 2019)